Search Within

Colette Ngozi Owens

Formats
  1. Meeting Abstract (51)
  2. Journal Article (21)
  3. Book Section (4)
  4. Research Letter (2)
Groups
  1. Department of Medicine (78)
  2. Hematologic Malignancies, Division of (78)
  3. Weinberg Fellows (78)
  4. Center for Hematologic Malignancies (71)
  5. Lymphoma (71)
  6. Population Sciences Research Program (54)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Anita Kumar (59)
  3. Ariela Noy (57)
  4. Paul Hamlin (55)
  5. Maria Palomba (53)
  6. Alison Moskowitz (50)

More People

Years
  1. 2025 (4)
  2. 2024 (17)
  3. 2023 (14)
  4. 2022 (7)
  5. 2021 (14)
  6. 2020 (11)

More Years

Publications
  1. Blood (44)
  2. Journal of Clinical Oncology (7)
  3. Blood Advances (5)
  4. Hematological Oncology (5)
  5. Blood Cancer Journal (3)
  6. Haematologica (3)

More Publications

Publishers
  1. American Society of Hematology (49)
  2. American Society of Clinical Oncology (7)
  3. Wiley Blackwell (6)
  4. Ferrata Storti Foundation (3)
  5. Nature Publishing Group (3)
  6. Springer (3)

More Publishers

Results (78)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical characteristics and follow-up post-surgery of women with BIA-ALCL operated at a single institution
    Meeting Abstract

    Ghione, P.; Vorstenbosch, J.; Cordeiro, P. G.; Arcila, M. E.; Moskowitz, A. J.; Owens, C.; Galasso, N.; Nelson, J. A.; Dogan, A.; McCarthy, C. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Follicular lymphoma in the modern era: Survival, treatment outcomes, and identification of high-risk subgroups
    Journal Article

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Caron, P. C.; Falchi, L.; Hamilton, A.; more...
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save
  • Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma
    Journal Article

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Gerecitano, J. F.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save